Seres Therapeutics Inc. [MCRB] Insider Ege David S. sells 7,038 Shares – Insider Selling Alert


Seres Therapeutics Inc.’s filing revealed that its insider Ege David S. unloaded Company’s shares for reported $36527.0 on Apr 28. In the deal valued at $5.19 per share,7,038 shares were sold. As a result of this transaction, Ege David S. now holds 59,696 shares worth roughly $ 0.21 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Ege David S. sold 5,012 shares, generating $39,745 in total proceeds. Upon selling the shares at $7.93, the insider now owns 46,734 shares.

PT values the company’s stock at a premium of 70.67 to its Tuesday closing price.

Price Performance Review of MCRB

On Tuesday, Seres Therapeutics Inc. [NASDAQ:MCRB] saw its stock fall -3.03% to $3.52. On the same session, the stock had its day’s lowest price of $3.47, but rose to a high of $3.67. Over the last five days, the stock has lost -1.12%. Seres Therapeutics Inc. shares have fallen nearly -37.14% since the year began. Nevertheless, the stocks have fallen -32.18% over the past one year. While a 52-week high of $9.49 was reached on 04/18/23, a 52-week low of $3.26 was recorded on 08/17/23. SMA at 50 days reached $4.31, while 200 days put it at $5.28. A total of 3.2 million shares were traded, compared to the trading of 1.79 million shares in the previous session.

Levels Of Support And Resistance For MCRB Stock

The 24-hour chart illustrates a support level at 3.44, which if violated will result in even more drops to 3.35. On the upside, there is a resistance level at 3.64. A further resistance level may holdings at 3.75. The Relative Strength Index (RSI) on the 14-day chart is 34.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.36%. Stochastics %K at 60.23% indicates the stock is a holding.

How much short interest is there in Seres Therapeutics Inc.?

A steep rise in short interest was recorded in Seres Therapeutics Inc. stocks on Aug 14, 2023, growing by 1.17 million shares to a total of 23.35 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 22.18 million shares. There was a rise of 5.01%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 34.50% of the overall stock float, the days-to-cover ratio (short ratio) rose to 11.23.

Seres Therapeutics Inc. [MCRB] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 19,185,208 shares, or roughly 15.00% of the outstanding MCRB shares. In other words, the investor’s shares have risen by 273,750 from its previous 13-F filing of 18911458.0. Additionally, Federated Global Investment Manag decreased -25.41% of its stake after which the total value it holdings stand at $54,808,993, while SSgA Funds Management, Inc. added 127.29% of its stake to hold $41.2 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 1,327,621 shares of Seres Therapeutics Inc., while Janus Henderson Investors US LLC bought -5,227,873 shares. At present, The Vanguard Group, Inc. is holding 5,125,781 shares valued at $24.66 million. Eversept Partners LP owned 3,076,756 shares of the company at the time of its most recent 13F filing, worth $14.8 million.

According to FactSet, Seres Therapeutics Inc.’s share price will average $9.83 in the next year, based on opinions of analysts polled by the firm. This is up nearly 203.03 percent from its previous closing price of $3.63. Analysts expect Seres Therapeutics Inc. stock to reach the higher price of $15.00, while the lowest price estimate is $4.00. However, 7 analysts have rated MCRB stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here